Erdafitinib
Balversa (erdafitinib) is a small molecule pharmaceutical. Erdafitinib was first approved as Balversa on 2019-04-12. It is used to treat transitional cell carcinoma in the USA. It is known to target fibroblast growth factor receptor 2, fibroblast growth factor receptor 4, vascular endothelial growth factor receptor 2, fibroblast growth factor receptor 1, and fibroblast growth factor receptor 3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Balversa
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Erdafitinib
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BALVERSA | Johnson & Johnson | N-212018 RX | 2019-04-12 | 3 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| balversa | New Drug Application | 2024-08-22 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| transitional cell carcinoma | — | D002295 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ERDAFITINIB, BALVERSA, JANSSEN BIOTECH | |||
| 2027-01-19 | I-930 | ||
| 2024-04-12 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
44 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urinary bladder neoplasms | D001749 | — | C67 | 3 | 5 | 1 | — | 2 | 11 |
| Non-muscle invasive bladder neoplasms | D000093284 | — | — | — | 1 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 2 | 8 | — | — | 1 | 11 |
| Carcinoma | D002277 | — | C80.0 | 2 | 5 | — | — | 1 | 7 |
| Recurrence | D012008 | — | — | 1 | 5 | — | — | — | 6 |
| Lymphoma | D008223 | — | C85.9 | 2 | 4 | — | — | — | 6 |
| Transitional cell carcinoma | D002295 | — | — | 3 | 2 | — | — | 2 | 6 |
| Urologic neoplasms | D014571 | — | C64-C68 | 2 | 2 | — | — | 2 | 5 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | 4 | — | — | — | 4 |
| Glioma | D005910 | EFO_0000520 | — | — | 4 | — | — | — | 4 |
| Plasma cell neoplasms | D054219 | — | — | 1 | 3 | — | — | — | 3 |
| Prostatic neoplasms | D011471 | — | C61 | — | 3 | — | — | — | 3 |
Show 55 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 7 | — | — | — | — | 7 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Urethral neoplasms | D014523 | EFO_0003846 | — | 1 | — | — | — | — | 1 |
| Ureteral neoplasms | D014516 | EFO_0003844 | C66 | 1 | — | — | — | — | 1 |
| Pelvic neoplasms | D010386 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Erdafitinib |
| INN | erdafitinib |
| Description | Erdafitinib, sold under the brand name Balversa, is an anti-cancer medication. It is a small molecule inhibitor of fibroblast growth factor receptor (FGFR) used for the treatment of cancer. FGFRs are a subset of tyrosine kinases which are unregulated in some tumors and influence tumor cell differentiation, proliferation, angiogenesis, and cell survival. Astex Pharmaceuticals discovered the drug and licensed it to Janssen Pharmaceuticals for further development.
|
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1 |
Identifiers
| PDB | — |
| CAS-ID | 1346242-81-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3545376 |
| ChEBI ID | — |
| PubChem CID | 67462786 |
| DrugBank | DB12147 |
| UNII ID | 890E37NHMV (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
FGFR2
FGFR2
FGFR4
FGFR4
KDR
KDR
FGFR1
FGFR1
FGFR3
FGFR3
Organism
Homo sapiens
Gene name
FGFR2
Gene synonyms
BEK, KGFR, KSAM
NCBI Gene ID
Protein name
fibroblast growth factor receptor 2
Protein synonyms
bacteria-expressed kinase, BEK fibroblast growth factor receptor, CD332, K-sam, Keratinocyte growth factor receptor, KGFR, protein tyrosine kinase, receptor like 14
Uniprot ID
Mouse ortholog
Fgfr2 (14183)
fibroblast growth factor receptor 2 (P21803)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,786 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
931 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use